

Chemitope Glycopeptide, LLC

BioBAT
140 58th St 8th Floor
Brooklyn, NY 11220

Baptiste Aussedat, CEO

T 646-512-4207


baussedat@chemitopeglycopeptide.com

William Walkowicz, CSO

T 917-539-9263

bwalkowicz@chemitopeglycopeptide.com

<http://www.chemitopeglycopeptide.com>



CHEMITOPE

GLYCOPEPTIDE

Industry:

- X Pharma
- X Biotech
- Medical Device
- Diagnostic
- Other (declare)

Management:

- *Executive Leadership*
Baptiste Aussedat, PhD
William Walkowicz, PhD
- *Board*
Jeffrey Gardner, MBA
- *Scientific Advisory Board*
Barton F. Haynes, MD

Number of Employees: 2**Finance:**

- *Auditor* – None
- *Financing to Date*
\$200,000 – Friends & Family
- *Amount of Financing Sought*
\$500,000

Legal:

- *Corporate*
Frigon, Maher, and Stern, LLP
- *IP* – None

Executive Summary: Chemitope Glycopeptide is a boutique chemical manufacturing company. As pioneers in glycopeptide chemistry, we were chosen by the Duke Human Vaccine Institute (DHVI) to synthesize immunogens to be used in an HIV vaccine. Our most advanced candidate has elicited a broadly neutralizing response in non-human primates, the holy grail of an HIV vaccine. The validation of our unique approach with HIV will facilitate entry into other disease indications, such as therapeutic vaccines in oncology.

Company History: Chemitope was founded by two scientists at Memorial Sloan Kettering Cancer Center in the Laboratory for Bioorganic Chemistry, headed by Professor Samuel Danishefsky. Beginning in 2012, a collaboration led by Dr. Aussedat with a team the DHVI resulted in six publications and two patents. As the commercial and scientific opportunities arising from the fruitful collaboration became apparent, Drs. Aussedat and Walkowicz spun out of MSKCC and will open an independent lab in Brooklyn on June 1, 2018.

Market Opportunity / Unmet Need: An HIV vaccine providing 75% protection would generate \$2.2B in revenue annually. There is currently no FDA approved HIV vaccine.

Products/Services – Launched & Pipeline:

V3 Glycopeptide (HIV) – More than two dozen non-human primates immunized. No adverse events. One cohort showing broadly neutralizing response. Currently optimizing immunization schedule and CMC production for Third-Quarter 2019 IND filing.

V1V2 Glycopeptide (HIV) – Lead optimization. Initial NHP studies underway.

Commercial / Technical Milestones: Chemical synthesis of complex glycopeptides is uniquely challenging and expensive. Chemitope has streamlined the process and has demonstrated the technical capability to manufacture sufficient quantities to facilitate Phase I and II Clinical Trials for our lead clinical candidate.

Chemitope has received an advanced purchase order to be executed June 1 from DHVI for custom synthesis of modified glycans.

Intellectual Property: Negotiating licensing terms with DHVI for patent application *V3 Immunogens*.

Competition: Preventative HIV Vaccines in Phase III Clinical Trial; NIAID/Sanofi/GSK Phase II Clinical Trial; J&J

Financial Projections (Unaudited): Beginning in July 2019, Chemitope will be the sole provider of glycopeptides for the CHAVI-ID consortium, a multi-center effort centered at DHVI, whose focus is the design of immunogens for HIV vaccines. With this consistent non-dilutive funding, we will be able to validate glycopeptides as effective immunogens, which we can then translate to other indications.

Please indicate primary purpose of Presentation:

Investment: Proceeds from seed funding will be used to purchase capital equipment, secure licensing agreements, and generate new IP.